| 1. |
- Taylor, David M., et al.
(författare)
-
Reducing the stigma of long acting injectable antipsychotics : current concepts and future developments
- 2018
-
Ingår i: Nordic Journal of Psychiatry. - : Taylor & Francis. - 0803-9488 .- 1502-4725. ; 72:S1, s. S36-S39
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Long acting injectable antipsychotics (LAI-APs) are considered a major advance in psychiatric treatment concerning treatment adherence and outcomes. Yet, both, doctors and patients remain sceptical. Aim: To explain the rationale for using LAI-APs, review their effectiveness and explore barriers to use. Method: Clinical overview of LAI-APs from the patient and doctor’s perspective. Results: LAI-APs were developed to increase adherence to treatment, thereby improving treatment outcomes. LAI-APs may reduce the risk of relapse and hospitalisation. Yet, the evidence from the few meta-analyses available remains weak. Both patients and doctors may associate LAI-APs with stigma and coercion. Current means of improving adherence include more focus on the therapeutic relationship, better information, adverse effects minimisation and half-life extension of LAI-APs. Future means of improving adherence include novel administration techniques that abolish the need for injection. Conclusions: For both, clinicians and drug developers, drug adherence remains a major target for improving treatment outcomes.
|
|
| 2. |
- Velaga, Sitaram, et al.
(författare)
-
Reducing the stigma of long acting injectable antipsychotics : current concepts and future developments
- 2018
-
Ingår i: Conference proceedings of the 4th Masterclass Psychiatry. - : Taylor & Francis. ; , s. 30-33
-
Konferensbidrag (refereegranskat)abstract
- Background: Long acting injectable antipsychotics (LAIAPs) are considered a major advance in psychiatric treatment concerning treatment adherence and outcomes. Yet, both, doctors and patients, remain sceptical.Aim: To explain the rationale for using LAI-APs, review their effectiveness and explore barriers to use. Method: Clinical overview of LAI-APs from the patient and doctor perspective.Results: LAI-APs were developed to increase adherence to treatment, thereby improving treatment outcomes. LAI-APs may reduce risk of relapse and hospitalization. Yet, the evidence from the few meta-analyses available remains weak. Both patients and doctors may associate LAI-APs with stigma and coercion. Current means of improving adherence include more focus on the therapeutic relationship, better information, adverse effects minimization and halflife extension of LAI-APs. Future means of improving adherence include novel administration techniques that abolish the need for injection.Conclusions: For both, clinicians and drug developers, drug adherence remains a major target for improving treatment outcomes.
|
|
